Hsbc Holdings PLC Has $888,000 Stock Holdings in Bruker Co. (NASDAQ:BRKR)

Hsbc Holdings PLC lessened its position in Bruker Co. (NASDAQ:BRKR) by 38.9% in the second quarter, according to its most recent disclosure with the SEC. The firm owned 13,920 shares of the medical research company’s stock after selling 8,869 shares during the period. Hsbc Holdings PLC’s holdings in Bruker were worth $888,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Assetmark Inc. increased its stake in Bruker by 24.7% during the 4th quarter. Assetmark Inc. now owns 1,005 shares of the medical research company’s stock valued at $74,000 after purchasing an additional 199 shares in the last quarter. Treasurer of the State of North Carolina raised its holdings in shares of Bruker by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 48,608 shares of the medical research company’s stock worth $3,572,000 after acquiring an additional 468 shares during the last quarter. TFO Wealth Partners LLC lifted its position in Bruker by 30,866.7% in the 4th quarter. TFO Wealth Partners LLC now owns 929 shares of the medical research company’s stock valued at $68,000 after acquiring an additional 926 shares in the last quarter. KBC Group NV boosted its stake in Bruker by 6.6% during the 4th quarter. KBC Group NV now owns 38,051 shares of the medical research company’s stock valued at $2,796,000 after purchasing an additional 2,356 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB bought a new stake in Bruker during the 4th quarter worth approximately $1,176,000. Institutional investors own 79.52% of the company’s stock.

Bruker Stock Performance

NASDAQ:BRKR opened at $70.67 on Friday. Bruker Co. has a 1 year low of $53.79 and a 1 year high of $94.86. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.65 and a quick ratio of 0.75. The business has a fifty day simple moving average of $65.08 and a two-hundred day simple moving average of $71.96. The company has a market capitalization of $10.27 billion, a P/E ratio of 25.70, a P/E/G ratio of 2.43 and a beta of 1.18.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Tuesday, August 6th. The medical research company reported $0.52 EPS for the quarter, meeting the consensus estimate of $0.52. The business had revenue of $800.70 million for the quarter, compared to the consensus estimate of $799.44 million. Bruker had a net margin of 11.29% and a return on equity of 24.92%. The company’s revenue was up 17.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.50 earnings per share. On average, analysts expect that Bruker Co. will post 2.61 earnings per share for the current year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 16th. Investors of record on Monday, September 2nd were issued a dividend of $0.05 per share. The ex-dividend date of this dividend was Friday, August 30th. This represents a $0.20 dividend on an annualized basis and a yield of 0.28%. Bruker’s dividend payout ratio (DPR) is 7.27%.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the company. TD Cowen cut their target price on Bruker from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Bruker in a research note on Monday, June 3rd. They issued a “buy” rating and a $85.00 target price for the company. Citigroup dropped their price target on shares of Bruker from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Wednesday, July 10th. Wells Fargo & Company assumed coverage on shares of Bruker in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $78.00 price objective for the company. Finally, The Goldman Sachs Group dropped their target price on shares of Bruker from $72.00 to $60.00 and set a “sell” rating on the stock in a research report on Tuesday, July 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have given a buy rating to the stock. According to MarketBeat, Bruker has a consensus rating of “Moderate Buy” and a consensus target price of $81.40.

About Bruker

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.